-
公开(公告)号：US20170305932A1
公开(公告)日：2017-10-26
申请号：US15513357
申请日：2015-10-02
申请人： UCB Biopharma SPRL , Sanofi
发明人： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号： C07D519/00 , C07D495/18 , C07D487/18 , C07D491/18 , C07F7/18 , C07D513/18
CPC分类号： C07D519/00 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D471/18 , C07D487/08 , C07D487/18 , C07D491/08 , C07D491/18 , C07D493/18 , C07D495/08 , C07D495/18 , C07D513/18 , C07F7/1804
摘要： A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US20200046723A1
公开(公告)日：2020-02-13
申请号：US16497217
申请日：2018-04-24
申请人： UCB Biopharma SPRL , SANOFI
发明人： Daniel Christopher Brookings , Teresa De Haro Garcia , Yann Foricher , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Malcolm Maccoss , Mengyang Xuan , Zhaoning Zhu
IPC分类号： A61K31/55 , C07D487/18
摘要： A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US10202405B2
公开(公告)日：2019-02-12
申请号：US15513357
申请日：2015-10-02
申请人： UCB Biopharma SPRL , Sanofi
发明人： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号： C07D519/00 , C07F7/18 , C07D471/18 , C07D487/18 , C07D493/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D495/18 , C07D513/18
摘要： A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US10906919B2
公开(公告)日：2021-02-02
申请号：US16220847
申请日：2018-12-14
申请人： UCB Biopharma SRL , Sanofi
发明人： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号： C07D519/00 , C07F7/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18
摘要： A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US11912721B2
公开(公告)日：2024-02-27
申请号：US17102790
申请日：2020-11-24
申请人： UCB Biopharma SRL , Sanofi
发明人： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm MacCoss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号： C07D519/00 , C07D491/08 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18 , C07F7/18 , A61K31/4184 , A61K31/506 , A61K31/55
CPC分类号： C07D519/00 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D471/18 , C07D487/08 , C07D487/18 , C07D491/08 , C07D491/18 , C07D493/18 , C07D495/08 , C07D495/18 , C07D513/18 , C07F7/1804
摘要： A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US20210155637A1
公开(公告)日：2021-05-27
申请号：US17102790
申请日：2020-11-24
申请人： UCB Biopharma SRL , Sanofi
发明人： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC分类号： C07D519/00 , C07F7/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D471/18 , C07D487/18 , C07D493/18 , C07D495/18 , C07D513/18
摘要： A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US20230250105A1
公开(公告)日：2023-08-10
申请号：US18175030
申请日：2023-02-27
申请人： UCB Biopharma SRL , SANOFI
发明人： Daniel Christopher Brookings , Teresa De Haro Garcia , Yann Foricher , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Malcolm Maccoss , Mengyang Xuan , Zhaoning Zhu
IPC分类号： C07D487/18
CPC分类号： C07D487/18 , C07B2200/05
摘要： A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US20210252012A1
公开(公告)日：2021-08-19
申请号：US17176018
申请日：2021-02-15
申请人： UCB Biopharma SRL , SANOFI
发明人： Daniel Christopher Brookings , Teresa De Haro Garcia , Yann Foricher , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Malcolm Maccoss , Mengyang Xuan , Zhaoning Zhu
IPC分类号： A61K31/55 , C07D487/18
摘要： A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09120812B2
公开(公告)日：2015-09-01
申请号：US14374838
申请日：2013-01-25
申请人： SANOFI
发明人： Alain Braun , Olivier Crespin , Yann Foricher , Gilbert Marciniak , Nicolas Muzet , Eric Nicolai , Cecile Pascal , Bertrand Vivet , Fabrice Viviani
IPC分类号： C07D498/04 , C07D519/00
CPC分类号： C07D498/04 , C07D519/00
摘要： The invention relates to bicyclic heterocyclic derivatives of general formula (I) to a process for preparing them and to the therapeutic use thereof.
摘要翻译： 本发明涉及通式（I）的双环杂环衍生物及其制备方法及其治疗用途。
-
10.发明公开公开(公告)号：US20240124408A1
公开(公告)日：2024-04-18
申请号：US18267644
申请日：2021-12-16
申请人： Sanofi
发明人： Paul Justin Mueller , Florian Auger , Guillaume Begis , Yann Foricher , Christoph Grebner , Stéphane Hourcade , Stéphanie Meyfroot , Sven Ruf , Klaus Wirth
IPC分类号： C07D305/06 , A61P11/04 , C07C235/40 , C07C237/12
CPC分类号： C07D305/06 , A61P11/04 , C07C235/40 , C07C237/12
摘要： Compounds of formula (1):
wherein R1 represents a —C(R2)(R3)—[C(R4)(R5)]m-L-R6 group or —R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment of oropharyngeal dysphagia.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.031 秒)
